significant factors of clinical outcomes with olaparib in patients with ovarian cancer
Published 9 years ago • 121 plays • Length 1:29Download video MP4
Download video MP3
Similar videos
-
2:21
dr. rafii discusses clinical outcomes with olaparib in patients with ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
4:17
case 2: olaparib in brca-mutated ovarian cancer
-
1:11
solo3 highlights toxicities with olaparib in ovarian cancer
-
2:07
maintenance olaparib in patients with ovarian cancer
-
11:22
olaparib in ovarian cancer
-
2:05
dr. leath on clinical outcomes and quality of life in ovarian cancer
-
59:46
cgc webinar: accelerating pediatric cancer research: harnessing the power of the openpedcan project
-
0:55
a study of olaparib and cediranib in ovarian cancer
-
0:40
dr. willmott on fda approval of maintenance olaparib in ovarian cancer
-
1:04
olaparib maintenance therapy in ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
1:50
results for maintenance olaparib in brca-mutated platinum-sensitive ovarian cancer
-
2:48
rationale for olaparib in advanced ovarian cancer
-
3:56
solo1 trial of maintenance olaparib in advanced ovarian cancer | susana banerjee
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
3:37
selecting patients to be treated with maintenance olaparib in the paola-1 trial
-
2:13
dr. patel on cediranib versus olaparib in recurrent platinum-sensitive ovarian cancer
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer